Evidence‑Based Treatment Recommendations for Vitiligo
Initial Management of Recent‑Onset Disease
Topical Therapies for Localized Vitiligo
Phototherapy for Widespread Vitiligo
Special Populations
Children and Adolescents
Adults with Light Skin Types (I‑II)
Surgical Interventions for Stable Disease
Therapies to Avoid
Depigmentation for Extensive Disease
Essential Adjunctive Care
Psychological Support
Monitoring
Guideline Position on Sunscreen Type for Vitiligo Patients
Recommendations from Vitiligo Treatment Guidelines
- Current vitiligo treatment guidelines do not recommend either physical (mineral) or chemical sunscreens over the other; the choice should be based on cosmetic acceptability and patient preference rather than disease‑specific contraindications 11, 12, 13.
Evidence‑Based Management of Segmental Vitiligo
Topical Immunomodulators
- Tacrolimus or pimecrolimus are recommended as alternatives to highly potent topical corticosteroids because they provide a superior short‑term safety profile and avoid steroid‑related skin atrophy and telangiectasia. (Level B evidence – comparative safety data) 14
Levamisole
Levamisole has no specific evidence for segmental vitiligo and is absent from current vitiligo treatment guidelines, reflecting a low‑quality evidence base. (Level C – lack of targeted studies) 15, 16, 17, 18, 19, 14
Levamisole should not be used, either alone or in combination, for segmental vitiligo because of the absence of subtype‑specific data and guideline support. (Level C) 15, 16, 17, 18, 19, 14
Surgical Eligibility Criteria (stable segmental disease)
| Criterion | Evidence |
|---|---|
| No new lesions for ≥12 months | [15, 16, 17, 18] |
| No Koebner phenomenon | [15, 16, 17, 18] |
| No extension of existing lesions for ≥12 months | [15, 16, 17, 18] |
| Lesion located on a cosmetically sensitive site (face, hands, or other visible area) | [15, 16, 17, 18] |
These criteria are endorsed by expert consensus guidelines for surgical intervention in stable segmental vitiligo. (Level B)
Preferred Surgical Techniques
Split‑skin grafting is the preferred technique, achieving excellent repigmentation (>75%) in 83 % of cases. (Level B – prospective outcome data) 16, 18
Autologous epidermal suspension applied to laser‑abraded lesions followed by NB‑UVB or PUVA is considered the optimal transplantation procedure, though it requires specialized facilities. (Level B – expert recommendation) 15, 16, 17, 18
Minigraft procedures are not recommended because they are associated with a high incidence of side effects and poor cosmetic outcomes (cobblestone and polka‑dot appearance). (Level C – observational reports) 15, 16, 17, 18
Suction blister transfer shows a 50 % success rate, with higher efficacy in segmental/focal disease and in patients younger than 20 years. (Level C – retrospective data) 15, 16
Clinical Decision Algorithm
If a patient meets all surgical eligibility criteria, refer for split‑skin grafting or autologous epidermal suspension, as these modalities provide the highest repigmentation rates for stable segmental vitiligo. (Level B) 15, 16, 17, 18
If surgery is declined or not feasible, initiate tacrolimus 0.1 % ointment twice daily as first‑line medical therapy, acknowledging modest repigmentation outcomes. (Level B – standard practice)
Consider adding narrow‑band UVB to tacrolimus if monotherapy fails after 6 months, given synergistic efficacy reported in combination studies. (Level B – combination therapy data)
Segmental Vitiligo – Evidence‑Based Management
Distinctive Clinical Features
- The unilateral, dermatomal distribution and rapid stabilization of segmental vitiligo differentiate it from non‑segmental vitiligo and dictate a distinct therapeutic algorithm. 20
Surgical Management
- In patients with stable segmental vitiligo, split‑skin grafting achieves > 75 % repigmentation in ≈ 83 % of cases and provides superior cosmetic outcomes. 20
- Minigraft procedures are associated with high complication rates and poor cosmetic appearance (cobblestone/polka‑dot effect) and should be avoided. 20
Pharmacologic Contraindications
- Prolonged use (> 2 months) of potent topical corticosteroids should be avoided because of the risk of skin atrophy; brief trials may be considered when necessary. 20
- Oral dexamethasone is not recommended for segmental vitiligo due to an unacceptable risk‑benefit profile. 20
Phototherapy Recommendations
- Narrowband UVB (NB‑UVB) phototherapy three times weekly is indicated for widespread segmental vitiligo or when the disease significantly impairs quality of life. 21
- NB‑UVB is more effective and safer than PUVA for vitiligo treatment. [21][22]
- For patients with skin phototypes I–III, NB‑UVB should be limited to a maximum of 200 treatment sessions. 21
- PUVA therapy should be limited to 150 sessions and is not recommended for children. 22